Skip to Content Subscribe Our Offers My Account Manage My Subscriptions FAQ Newsletters Canada Canadian True Crime Canadian Politics Health World Israel & Middle East Financial Post NP Comment Longreads Puzzmo Diversions Comics NP News Quiz New York Times Crossword Horoscopes Life Eating & Drinking Style Sponsored Play for Ontario Travel Travel Canada Travel USA Travel International Cruises Travel Essentials Culture Books Celebrity Movies Music Theatre Television Business Essentials Advice Lives Told Tails Told Shopping Buy Canadian Home Living Outdoor Living Kitchen & Dining Tech Style & Beauty Personal Care Entertainment & Hobbies Gift Guide Travel Guide Amazon Prime Day Deals Savings National Post Store More Sports Hockey Baseball Basketball Football Soccer Golf Tennis Driving Vehicle Research Reviews News Gear Guide Obituaries Place an Obituary Place an In Memoriam Classifieds Place an Ad Celebrations Working Business Ads Archives Healthing Epaper Manage Print Subscription Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ Newsletters Canada World Financial Post NP Comment Longreads Puzzmo Diversions Life Shopping Epaper Manage Print Subscription HomeNewsCanadaModerna authorized to launch its Ebola vaccine clinical trials in CanadaThe vaccine relies on the same mRNA technology used in the pharmaceutical company's Covid-19 vaccineAuthor of the article:Last updated 19 minutes ago You can save this article by registering for free here. Or sign-in if you have an account.A hygiene worker helps a doctor put on personal protective equipment (PPE) before caring for patients with Ebola in the Democratic Republic of Congo last month. Canada's ministry of health has granted Moderna authorization to begin clinical trials on a vaccine against the Bundibugyo strain that has killed more than 1,700 in the African nation. Photo by BENEDICTION MURHABAZI /AFP via Getty ImagesCanada has authorized U.S. pharmaceutical giant Moderna to begin clinical trials for a vaccine against the Bundibugyo strain of Ebola, the Canadian health ministry announced Tuesday.Enjoy the latest local, national and international news.Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events.Unlimited online access to National Post.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles including the New York Times Crossword.Support local journalism.Enjoy the latest local, national and international news.Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events.Unlimited online access to National Post.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles including the New York Times Crossword.Support local journalism.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountorThe Phase 1 trial of the mRNA vaccine “will assess the candidate vaccine’s safety, determine the right dosage range and identify any side effects,” according to the ministry.No Ebola cases have so far been recorded in Canada.Get a dash of perspective along with the trending news of the day in a very readable format.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of NP Posted will soon be in your inbox.We encountered an issue signing you up. Please try againAs part of the trial, a group of healthy participants will receive a dose of the vaccine to assess the antibody response to the Bundibugyo strain.If the results are positive, the vaccine will advance to further clinical trials involving larger groups of participants.The vaccine relies on the same mRNA technology used in Moderna’s Covid-19 vaccine.Canada, which closed its borders on July 20 to all foreign nationals who had recently been in the Democratic Republic of Congo (DRC), has reached an agreement with the company to manufacture the vaccine on Canadian soil.There is currently no approved vaccine or treatment for the Bundibugyo variant behind the Ebola outbreak declared on May 15.Other vaccine candidates are also under development.A vaccine described by the WHO as the “most promising,” known as rVSV Bundibugyo, is to be developed by Singapore-based Hilleman Laboratories.Meanwhile, in late July, the first volunteer received the initial dose of another Bundibugyo vaccine developed by the University of Oxford in Britain, which uses the same technology as AstraZeneca’s Covid-19 vaccine.Treatments are also undergoing clinical trials in line with recommendations from the WHO.Ebola, which is transmitted through contact with bodily fluids and causes hemorrhagic fever, has killed more than 1,700 people in the DRC since May.Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark nationalpost.com and sign up for our daily newsletter, Posted, here. Join the Conversation This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.